Prognostic factors for response to sildenafil in patients with erectile dysfunction

被引:75
作者
Martínez-Jabaloyas, JM [1 ]
Gil-Salom, M [1 ]
Villamón-Fort, R [1 ]
Pastor-Hernández, F [1 ]
Martínez-García, R [1 ]
García-Sisamón, F [1 ]
机构
[1] Univ Valencia, Hosp Clin, Dept Urol, E-46010 Valencia, Spain
关键词
sildenafil; impotence; prognosis; therapeutics;
D O I
10.1159/000049850
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective:To assess the clinical efficacy of sildenafil as treatment for erectile dysfunction (ED) the factors associated with treatment failure were investigated. Methods: Open, prospective study including 244 patients suffering from ED who were evaluated by anamnesis, physical exploration, blood test, dynamic penile color duplex ultrasonography and Sexual Health Inventory for Male (SHIM). The efficacy of sildenafil was assessed by repeating the SHIM 2 months after therapy, independent of the final dose used. Side effects were also recorded. Factors influencing treatment outcome were evaluated by univariate and multivariate statistical analysis. Results: Overall, sildenafil was effective in 56.8% of 213 eligible patients. When the etiologic diagnosis was not included in the multivariate analysis, antecedents of diabetes mellitus, non-nerve-sparing radical prostatectomy and SHIM basal score were selected as predictors of a poor response. In a second analysis including etiologic diagnosis, only SHIM basal score and etiological diagnosis proved to be of prognostic value. Side effects were noticed by 24.4% of patients, none of them being severe. Conclusions: Sildenafil is a rather effective and well-tolerated treatment for ED. The basal severity of ED and etiological diagnosis are the prognostic factors most significantly associated with treatment outcome. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:641 / 646
页数:6
相关论文
共 20 条
[1]   ERECTILE DYSFUNCTION IN DIABETIC MEN - THE NEUROLOGICAL FACTOR REVISITED [J].
BEMELMANS, BLH ;
MEULEMAN, EJH ;
DOESBURG, WH ;
NOTERMANS, SLH ;
DEBRUYNE, FMJ .
JOURNAL OF UROLOGY, 1994, 151 (04) :884-889
[2]   A positive pharmacological erection test does not rule out arteriogenic erectile dysfunction [J].
Cormio, L ;
Nisen, H ;
Selvaggi, FP ;
Ruutu, M .
JOURNAL OF UROLOGY, 1996, 156 (05) :1628-1630
[3]  
DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
[4]   IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
FELDMAN, HA ;
GOLDSTEIN, I ;
HATZICHRISTOU, DG ;
KRANE, RJ ;
MCKINLAY, JB .
JOURNAL OF UROLOGY, 1994, 151 (01) :54-61
[5]  
GASION JPB, 2000, ACTAS UROL ESP S, V24, P40
[6]   Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study [J].
Giuliano, F ;
Montorsi, F ;
Mirone, V ;
Rossi, D ;
Sweeney, M .
JOURNAL OF UROLOGY, 2000, 164 (03) :708-711
[7]   Oral sildenafil in the treatment of erectile dysfunction [J].
Goldstein, I ;
Lue, TF ;
Padma-Nathan, H ;
Rosen, RC ;
Steers, WD ;
Wicker, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1397-1404
[8]   Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year [J].
Hatzichristou, DG ;
Apostolidis, A ;
Tzortzis, V ;
Ioannides, E ;
Yannakoyorgos, K ;
Kalinderis, A .
JOURNAL OF UROLOGY, 2000, 164 (04) :1197-1200
[9]   Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment [J].
Jarow, JP ;
Burnett, AL ;
Geringer, AM .
JOURNAL OF UROLOGY, 1999, 162 (03) :722-725
[10]  
Junemann K., 1991, ERECTILE DYSFUNCTION, P104